Calamos Advisors LLC Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Calamos Advisors LLC trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,211 shares of the biopharmaceutical company’s stock after selling 173 shares during the period. Calamos Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $11,603,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Annis Gardner Whiting Capital Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $26,000. Sunbelt Securities Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $25,000. Fortitude Family Office LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $31,000. Bruce G. Allen Investments LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $40,000. Finally, Sutton Wealth Advisors Inc. grew its position in shares of Regeneron Pharmaceuticals by 38.2% in the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 13 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently commented on REGN. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $1,189.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. Barclays raised their price objective on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 23rd. Truist Financial reissued a “buy” rating and set a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. BMO Capital Markets raised their price objective on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a research report on Monday, February 5th. Finally, Sanford C. Bernstein started coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 price objective on the stock. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $976.41.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $982.05, for a total transaction of $98,205.00. Following the completion of the transaction, the director now directly owns 18,282 shares in the company, valued at approximately $17,953,838.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $982.05, for a total transaction of $98,205.00. Following the completion of the transaction, the director now directly owns 18,282 shares in the company, valued at approximately $17,953,838.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bonnie L. Bassler sold 827 shares of the firm’s stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total transaction of $793,093.00. Following the transaction, the director now owns 1,382 shares of the company’s stock, valued at $1,325,338. The disclosure for this sale can be found here. In the last three months, insiders sold 13,729 shares of company stock worth $13,124,641. 8.83% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Stock Up 0.3 %

Shares of NASDAQ REGN opened at $896.82 on Friday. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 52 week low of $684.80 and a 52 week high of $998.33. The firm has a 50-day moving average price of $953.01 and a 200 day moving average price of $891.10. The stock has a market capitalization of $98.43 billion, a price-to-earnings ratio of 25.81, a price-to-earnings-growth ratio of 2.58 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The firm had revenue of $3.43 billion during the quarter, compared to analysts’ expectations of $3.29 billion. During the same quarter last year, the business earned $10.96 earnings per share. The business’s revenue for the quarter was up .6% compared to the same quarter last year. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.59 EPS for the current fiscal year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.